CORE--VIROLOGY CORE LABORATORY

艾滋病是一种病毒性疾病，临床进展与 增加病毒负荷。 将准确评估体内HIV-1水平 对监测治疗效果至关重要。 HIV-1的复制活性 现在可以通过常规免疫测定在一定程度上确定患者中的 血清中p24核心蛋白和病毒分离。 这两种病毒学 多年来，我们的实验室一直在使用这些测试， 自1984年以来，我们的出版物都有很好的记录。 此外，我们 第一个开发定量培养，可以确定 血浆和外周血单核细胞中HIV-1的感染滴度 患者的细胞。 此外，我们还利用这些终点稀释 用于证明存在或不存在以下物质的体内功效的测定： 抗病毒剂。 在过去的两年里，定量HIV-1 DNA在 本实验室也实现了对临床标本的PCR扩增。 这种定量PCR技术可以检测波动 在我们遇到的患者中HIV-1载量。 我们现在提议 p24抗原检测和HIV-1培养作为临床的常规服务 在纽约大学ACTG进行的试验。 在特定的临床情况下， 还将进行定量培养和PCR检测，以确定 新治疗剂的抗病毒活性。

AIDS is a viral disease, and clinical progression is associated with increased viral burden. Accurate assessment of HIV-1 level in vivo will be critical for monitoring treatment efficacy. Replicative activity of HIV-1 in patients can now be determined to an extent by routine immunoassay for p24 core protein in serum and by virus isolation. both of these virologic tests have been used in our laboratory for many years, and this expertise is well documented by our publications since 1984. In addition, we were the first to develop quantitative cultures which can determine the infectious titers of HIV-1 in the plasma and peripheral blood mononuclear cells of patients. Furthermore, we have utilized these end-point-dilution assays to demonstrate the presence or absence of in vivo efficacy of antiviral agents. In the past two years, quantitation of HIV-1 DNA in clinical samples by PCR methods has also been achieved in our laboratory. This quantitative PCR technique has permitted the detection of fluctuations in HIV-1 load in the patients encountered by us. We now propose to perform p24 antigen assays and HIV-1 cultures as a routine service for the clinical trials conducted at the NYU ACTG. In select clinical situations, quantitative culture and PCR tests will also be done to determine the antiviral activity of new therapeutic agents.